Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roberta D'Aniello

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
Cancers|March 13, 2024
Translational Insights in the Landscape of Salivary Gland Cancers: Ready for a New Era?Francesco Perri, Roberta Fusco, Francesco Sabbatino, et al.
Plos One|January 9, 2019
Costs of clinical trials with anticancer biological agents in an Oncologic Italian Cancer Center using the activity-based costing methodologyGiacomo Pascarella, Arturo Capasso, Antonio Nardone, et al.
Risk Management and Healthcare Policy|March 3, 2026
An ISO 31000-Based Risk Matrix for Risk Management in Anticancer Drug Prescription, Compounding, and Administration for Lung Cancer Patients Treated in a Day Hospital SettingAlessandro Morabito, Piera Maiolino, Stefania D'Auria, et al.
BMC Cancer|November 26, 2016
Phase II clinical study of valproic acid plus cisplatin and cetuximab in recurrent and/or metastatic squamous cell carcinoma of Head and Neck-V-CHANCE trialFrancesco Caponigro, Elena Di Gennaro, Franco Ionna, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
Cancers|March 13, 2024
Translational Insights in the Landscape of Salivary Gland Cancers: Ready for a New Era?Francesco Perri, Roberta Fusco, Francesco Sabbatino, et al.
Plos One|January 9, 2019
Costs of clinical trials with anticancer biological agents in an Oncologic Italian Cancer Center using the activity-based costing methodologyGiacomo Pascarella, Arturo Capasso, Antonio Nardone, et al.
Risk Management and Healthcare Policy|March 3, 2026
An ISO 31000-Based Risk Matrix for Risk Management in Anticancer Drug Prescription, Compounding, and Administration for Lung Cancer Patients Treated in a Day Hospital SettingAlessandro Morabito, Piera Maiolino, Stefania D'Auria, et al.
BMC Cancer|November 26, 2016
Phase II clinical study of valproic acid plus cisplatin and cetuximab in recurrent and/or metastatic squamous cell carcinoma of Head and Neck-V-CHANCE trialFrancesco Caponigro, Elena Di Gennaro, Franco Ionna, et al.
Pageof 2